BioCentury | Nov 9, 2015
Company News

Stanford University, Abeona Therapeutics deal

Stanford granted Abeona a license to an adeno-associated virus (AAV) delivery vector to treat Fanconi anemia. Abeona said the license augments a June deal with the University of Minnesota granting the company rights to ABO-301...
BioCentury | Jun 29, 2015
Company News

University of Minnesota, Abeona Therapeutics deal

The university granted Abeona exclusive, worldwide rights to CRISPR- Cas9 gene editing technology and related IP to develop products for non-cancer indications, including rare blood disorders. Abeona’s lead product using the technology is ABO-301 , an...
Items per page:
1 - 2 of 2